MARATTO

article · Cureus

Plasmablastic Lymphoma Masquerading as Plasma Cell Myeloma: A Case Report

20254 citationsOpen accessMohamed I University

Abstract

Plasmablastic lymphoma (PBL) is an uncommon and aggressive type of B-cell lymphoma, and it primarily affects individuals with compromised immune systems, particularly human immunodeficiency virus (HIV)-positive patients. It has a strong predilection for the oral cavity and a high association with Epstein-Barr virus (EBV) infection, with only rare extra-oral and EBV-negative cases. Tumor cells in PBL are represented by immature plasma cells known as plasmablasts, a morphological appearance shared with many B-cell and plasma cell neoplasms, which makes the distinction very challenging among these entities, especially in extra-oral locations and EBV-negative cases. PBL is characterized by an aggressive clinical outcome, with a very poor prognosis. Here, we describe an unusual case involving a 72-year-old patient who was previously diagnosed with plasma cell myeloma, which exhibited unusually aggressive and refractory progression; histomorphological investigations were consistent with an extra-oral, EBV-negative PBL. The rapid disease progression and lymph node involvement along with the presence of plasmablastic morphology raised the suspicion of a PBL. Throughout this case, we highlight the importance of a complete histopathological and immunohistochemical examination with correlation with clinical manifestations to ensure a precise diagnosis, particularly in extra-oral, EBV-negative cases.

Research topics

  • Viral-associated cancers and disorders
  • Histiocytic Disorders and Treatments
  • Lymphoma Diagnosis and Treatment

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.7759/cureus.77310

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.